Updated July 2026 · 8 min read

Thrombotic Thrombocytopenic Purpura: The ICU Nurse's Guide

Part of the ICU Emergencies Hub — browse every related guide in one place.

Thrombotic thrombocytopenic purpura is a hematologic emergency where recognition and treatment are separated by hours, not days. Untreated, it is frequently fatal; treated urgently with plasma exchange, most patients survive. The catch is that the intervention that saves the TTP patient — plasma exchange — is very different from the "give platelets" reflex a low platelet count usually triggers, and giving platelets here can make things worse.

The mechanism, in one paragraph

Normally an enzyme called ADAMTS13 chops the ultra-large von Willebrand factor (vWF) multimers the endothelium releases into smaller, well-behaved pieces. In TTP, ADAMTS13 is severely deficient — usually because an autoantibody has knocked it out (acquired TTP), occasionally because of an inherited defect. Without the enzyme, giant vWF strings stay in circulation and snag passing platelets into microthrombi throughout the microcirculation. Those clots consume platelets (thrombocytopenia) and shred red blood cells as they pass (hemolysis with schistocytes), while starving organs downstream — the brain and kidneys especially.

The classic pentad — but don't wait for all five

Textbooks list a pentad, but the full set appears in a minority of patients, and waiting for it costs lives. The two you need are the first two:

The lab fingerprint

TTP labs tell a consistent story: low platelets, hemolysis (high LDH, low haptoglobin, elevated indirect bilirubin, schistocytes on the smear), a negative direct antiglobulin (Coombs) test (the hemolysis is mechanical, not antibody-mediated against red cells), and — the point that separates it from DIC — normal or near-normal PT, PTT, and fibrinogen. An ADAMTS13 activity level is sent (severely low, typically <10%, confirms it), but the result often comes back after treatment has already started, so it confirms rather than gates the decision.

The treatment that can't wait: plasma exchange

Therapeutic plasma exchange (TPE / plasmapheresis) is the intervention that changed TTP from usually-fatal to usually-survivable. It does two jobs at once: it removes the autoantibody and the giant vWF multimers, and it replaces the missing ADAMTS13 by using plasma as the replacement fluid. It is a true emergency — the goal is to start within hours of the suspicion, often through a large-bore dialysis-type catheter. If plasma exchange cannot be started immediately, plasma infusion is a temporizing bridge, but it is not a substitute. Adjuncts include corticosteroids, rituximab to suppress the antibody, and caplacizumab (an anti-vWF agent) in many current protocols.

What the nurse is watching and doing

• Neuro checks. TTP's neurologic signs fluctuate — a patient can be lucid one hour and confused or seizing the next. Frequent, documented neuro assessments catch the swing.
• Bleeding and clotting signs. Petechiae, purpura, mucosal bleeding, and new focal deficits or chest pain.
• The apheresis catheter and circuit. Site care, patency, and watching for the complications of plasma exchange — citrate-related hypocalcemia (perioral tingling, cramps), allergic/transfusion reactions to plasma, and line issues.
• Serial labs. Platelet count and LDH are the response markers — a rising platelet count and falling LDH signal the exchange is working.
• Guarding the "no platelets" rule. Make sure a well-meaning cross-cover order for platelets in a bleeding-looking patient is questioned against the TTP diagnosis.

TTP vs. DIC vs. HIT

Three low-platelet emergencies, three different fingerprints. DIC consumes the clotting cascade, so its PT/PTT are prolonged and fibrinogen is low — the opposite of TTP's normal coags. HIT is tied to heparin exposure and causes clotting with generally normal coags and usually no brisk hemolysis. TTP is the one with hemolysis plus schistocytes, normal coags, and a low ADAMTS13, and it is the one where plasma exchange is the emergency. Getting the category right changes the entire treatment path.

Bottom line

TTP is a race. The moment you have unexplained thrombocytopenia plus a microangiopathic hemolytic anemia — low platelets, schistocytes, high LDH, low haptoglobin, normal coags — think TTP and push for urgent plasma exchange, the intervention that turns a frequently fatal disease into a survivable one. Hold platelet transfusions unless the patient is bleeding to death, watch the fluctuating neuro exam, and track the platelet count and LDH as your response markers. The nurse who recognizes the pattern early and protects the "no platelets" rule is directly in the survival pathway.

This article is general educational information for licensed clinicians and students, not medical advice or a substitute for your institution's protocols, pharmacy guidance, or a provider's orders. Always follow facility policy and verify doses independently.